Tyme Technologies (Tyme Technologies) Capex-to-Operating-Income : 0.00 (As of Jun. 2022)

View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Tyme Technologies's Capital Expenditure for the three months ended in Jun. 2022 was $0.00 Mil. Its Operating Income for the three months ended in Jun. 2022 was $-6.61 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Tyme Technologies Capex-to-Operating-Income Historical Data

The historical data trend for Tyme Technologies's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyme Technologies Capex-to-Operating-Income Chart

Tyme Technologies Annual Data

Trend

Nov12

Nov13

Nov14

Dec15

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Capex-to-Operating-Income

Get a 7-Day Free Trial

Tyme Technologies Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Tyme Technologies's Capex-to-Operating-Income

For the Biotechnology subindustry, Tyme Technologies's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyme Technologies's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyme Technologies's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Tyme Technologies's Capex-to-Operating-Income falls into.

Tyme Technologies Capex-to-Operating-Income Calculation

Tyme Technologies's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-23.076
	=	N/A

Tyme Technologies's Capex-to-Operating-Income for the quarter that ended in Jun. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-6.607
	=	N/A

Tyme Technologies (NAS:TYME) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Tyme Technologies Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Tyme Technologies's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyme Technologies (Tyme Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921

Website

https://www.tymeinc.com

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Executives

Michael Demurjian	director, 10 percent owner, officer: Chief Operating Officer	157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman	director, 10 percent owner, officer: CEO and Chief Science Officer	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl	director	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido	officer: Chief Financial Officer	C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini	officer: Corporate Controller	17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry	director	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M	officer: Acting Chief Medical Officer	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman	officer: EVP, Product Development	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor	officer: President and CFO	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin	officer: Chief Operating Officer	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105